Dalfampridine is Used for improving walking in patients with multiple sclerosis. It was first introduced by Merz Pharmaceuticals Llc in its drug Ampyra on Jan 22, 2010. 9 different companies have introduced drugs containing Dalfampridine.

Dalfampridine Patents

Given below is the list of patents protecting Dalfampridine, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Ampyra	US8007826	Sustained release aminopyridine composition	May 26, 2027	Merz
Ampyra	US8354437	Method of using sustained release aminopyridine compositions	Dec 22, 2026	Merz
Ampyra	US8440703	Methods of using sustained release aminopyridine compositions	Apr 08, 2025 (Expired)	Merz
Ampyra	US8663685	Sustained release aminopyridine composition	Jan 18, 2025 (Expired)	Merz
Ampyra	US9918973	Sustained release aminopyridine composition	Dec 13, 2024 (Expired)	Merz
Ampyra	US5540938	Formulations and their use in the treatment of neurological diseases	Jul 30, 2018 (Expired)	Merz

Add above patents to watchlist

Dalfampridine's Family Patents

Full family tree

Dalfampridine Generic API Manufacturers

Several generic applications have been filed for Dalfampridine. The first generic version for Dalfampridine was by Actavis Laboratories Fl Inc and was approved on Jan 23, 2017. And the latest generic version is by Rising Pharma Holding Inc and was approved on Jul 6, 2020.

Given below is the list of companies who have filed for Dalfampridine generic, along with the locations of their manufacturing plants worldwide.